0001654954-22-011096.txt : 20220812
0001654954-22-011096.hdr.sgml : 20220812
20220812060136
ACCESSION NUMBER: 0001654954-22-011096
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220809
FILED AS OF DATE: 20220812
DATE AS OF CHANGE: 20220812
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wu Hui-Lan
CENTRAL INDEX KEY: 0001901988
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41461
FILM NUMBER: 221157649
MAIL ADDRESS:
STREET 1: 8880 RIO SAN DIEGO DRIVE
STREET 2: SUITE 800
CITY: SAN DIEGO
STATE: CA
ZIP: 92108
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ainos, Inc.
CENTRAL INDEX KEY: 0001014763
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 751974352
STATE OF INCORPORATION: TX
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: AINOS, INC.
STREET 2: 8880 RIO SAN DIEGO DRIVE SUITE 800
CITY: SAN DIEGO
STATE: CA
ZIP: 92108
BUSINESS PHONE: 858-869-2986
MAIL ADDRESS:
STREET 1: AINOS, INC.
STREET 2: 8880 RIO SAN DIEGO DRIVE SUITE 800
CITY: SAN DIEGO
STATE: CA
ZIP: 92108
FORMER COMPANY:
FORMER CONFORMED NAME: AMARILLO BIOSCIENCES INC
DATE OF NAME CHANGE: 19960516
4
1
section16.xml
PRIMARY DOCUMENT
X0306
4
2022-08-09
0001014763
Ainos, Inc.
AIMD
0001901988
Wu Hui-Lan
8880 RIO SAN DIEGO DRIVE, SUITE 800
SAN DIEGO
CA
92108
false
true
false
false
Chief Financial Officer
Common Stock
2022-08-09
4
A
false
14705
3.40
A
18905
I
Daughter
Common Stock
11200
D
RSU
2022-07-28
4
A
false
2000000
.01
A
2022-09-30
2022-09-30
Common Stock
2000000
2000000
D
Yun-Huan Liao is Hui-Lan Wu's daughter
Reference is made to that certain Convertible Note Purchase Agreement and Convertible Promissory Note ("Note") in the principal amount of $50,000 between the Issuer and the Reporting Person's daughter, Yun-Han Liao. The Note bears no interest, matures on March 30, 2027, and is subject to mandatory conversion at a conversion price of 80% of an initial property offering price (if the Issuer conducts an initial public offering). On 08/11/22, the Company completed a public offering at a $4.25 per unit price ("Offering") and a 15-for-1 reverse stock split on 08/08/22 ("Reverse Split"). Transaction reflects an acquisition price of $3.40 per share (80% of the Offering) and the issued shares give effect to the Reverse Split.
Reference is made to the Restricted Stock Units (the "RSU") granted pursuant to an employment Mandate Agreement dated March 17, 2022 (the "Mandate Agreement") under the Company's 2021 Stock Incentive Plan. Each RSU represents a right to receive one (1) share of common stock upon vesting and the expiration of any applicable restricted period, or in the sole discretion of the Compensation Committee, the cash value thereof (or any combination thereof). Holders of RSUs have no rights or privileges as a stockholder. The shares underlying the RSUs will vest on September 30, 2022 and are may not be sold within 6 months of the grant date.
Prior to the Reverse Split discussed herein the Reporting Person beneficially owned 168,000 shares of common stock of the Issuer and after the Reverse Split, the Reporting Person owned 11,200 common stock.
Prior to the Reverse Split discussed herein the Reporting Person beneficially owned 63,000 shares of common stock of the Issuer and after the Reverse Split, and prior to the present issuances, 4,200 common stock. The amounts of securities beneficially owned in column 5 of this report is calculated from a post-split baseline of 4,200.
/s/ John Junyong Lee POA for Hui-Lan Wu
2022-08-11